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Abstract 
Background: This study describes the availability and characteristics of databases in 
Asian-Pacific countries and assesses the feasibility of a distributed network approach in the 
region. 
Methods: A Web-based survey was conducted among investigators using health care 
databases in the Asia-Pacific. Potential survey participants were identified through the Asian 
Pharmacoepidemiology Network.  
Results: A total of 11 databases participated in the survey. Database sources included 4 
nationwide claims databases from Japan, South Korea, and Taiwan; 2 nationwide electronic 
health records from Hong Kong and Singapore; a regional electronic health record from western 
China; 2 electronic health records from Thailand; and cancer and stroke registries from Taiwan. 
Conclusions: We identified 11 databases with capabilities for distributed network 
approaches. Many country-specific coding systems and terminologies have been already 
converted to international coding systems. The harmonization of health expenditure data is a 
major obstacle for future investigations attempting to evaluate issues related to medical costs. 
Keywords: AsPEN (Asian Pharmacoepidemiology Network); Distributed Network 
Approach; Claims Database; Electronic Health Records; Patient Registry 
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Introduction 
With the rapid development of electronic health records and computer technologies in 
North America and Europe, collaborative multi-database projects within or across nations have 
increased in the past decade.1-3 Multinational database studies can offer many advantages, 
including large sample sizes, cross-country comparisons, and generalizable results. Most 
importantly, collaboration among countries may also create partnerships that benefit public 
health.1,4 
Among European and North American multi-database networks, the distributed network 
approach has been widely used in the form of common data models.1-7 This approach allows 
individual data partners to maintain operational and physical control over their data.8-10 However, 
the feasibility of a common data model for heterogeneous databases in the Asia-Pacific region 
has not been assessed. 
The Asian Pharmacoepidemiology Network (AsPEN) was initiated in 2008 and now 
includes Australia, China, Hong Kong, India, Japan, Singapore, South Korea, Taiwan, and 
Thailand.11 The availability of claims databases or electronic health records from the AsPEN 
founding countries has been briefly introduced elsewhere,3 but without data component details 
and information on the new AsPEN countries. We sought to describe the availability and detailed 
characteristics of databases in Asian-Pacific countries. We also aimed to evaluate the capacity 
and feasibility of establishing a common data model for Asia-Pacific databases. 
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Methods 
We used a Web-based survey tool to conduct an online survey for investigators possessing 
or using health databases in the Asia-Pacific region.  
The survey included 142 questions about (1) the characteristics of the database; (2) access 
policies and restrictions; (3) population demographic characteristics; (4) data components coding 
systems used, including diagnoses, procedures, prescriptions, and laboratory data; (5) medical 
expenditures; and (6) traditional Chinese medicine or complementary medicine.  
Targeted databases were identified through the AsPEN website and recommendations 
provided by AsPEN members.11 A detailed description of our methods is included in the 
Appendix.  
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Results 
We invited 17 researchers from 13 databases to participate in the survey, and 15 (88.2%) 
researchers from 11 (84.6%) databases responded. A list of participating databases and their 
characteristics is presented in Table 1. Detailed descriptions of participating databases are 
presented in the Appendix. 
Unique patient identifiers and demographic characteristics, including sex and birth 
information, were available in the databases. Information on race and ethnicity was available in 
most electronic health record databases and registries but not in the claims databases. The clinical 
values for laboratory tests was available in all electronic health records and registries but not in 
the claims databases. Health expenditure information was available in all the claims databases but 
not in many electronic health records or registries. Date of death or patient status (ie, alive or 
dead) was not available in 3 claims databases, but could be estimated using eligibility for 
compulsory national insurance in 1 claims database. Other data components, including 
information on health care facilities and providers, are shown in Table 2. 
Table 3 details information found in databases about diagnoses, prescriptions, procedures, 
health expenses, and coding systems. 
Four databases contained longitudinal dispensing data for traditional Chinese medicine 
using a domestic coding system. Other information about traditional Chinese medicine, such as 
drugs records, is compiled in a manner consistent with Western medications (Table 4). 
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Discussion 
The survey included 11 databases, including health care utilization databases, electronic 
health records, and registries covering approximately 220 million individual records that are 
currently available for pharmacoepidemiologic and other clinical researchers. This provides an 
opportunity to establish a large-scale drug surveillance system for populations in the Asia-Pacific 
region. 
Japan, South Korea, and Taiwan, with universal insurance coverage, reimburse most 
health care services from their national budgets,12 which has led to the establishment of 
nationwide claims databases for administrative and reimbursement purposes, creating 
pharmacoepidemiologic data sources representative of the national population. Unlike claims 
databases, hospital-based electronic health records are usually compiled for clinical purposes,13 
and therefore could provide information to improve the validity of pharmacoepidemiologic 
studies by improving the specificity of outcome definitions and/or better measurement of 
confounding factors for adjustment. 
The representativeness of hospital-based electronic health records may depend on the 
proportion of hospitals included in the area. Nationwide systems, such as those in Hong Kong 
and Singapore, are representative of the entire population, but systems in China and Thailand 
may be less representative, as they represent data for specific regions only. The NHIRD, Hong 
Kong’s Clinical Data Analysis and Reporting System, Japan’s National Database (NDB), and 
South Korea’s Health Insurance Review and Assessment Service are population-based databases, 
enabling the calculation of the rate of incidence for specific events. 
Data privacy and related ethical issues are a major concern when using databases, 
resulting in a number of policies and restrictions to be established by data custodians. In 
particular, the privacy of nationwide health databases is paramount because of national security 
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issues.14,15 Currently, the data custodians of all Asia-Pacific databases included in this study 
request researchers obtain approval from an ethics review committee before accessing databases 
and require encryptions or truncations of specific data. Furthermore, we found that the custodians 
or regulators may partly restrict the availability of data. For example, researchers using NHIRD 
data receive data for 10% or less of the population.16 The NDB is usually not available for 
purchase and may only be shared in some cooperative research. Alternatively, the Japan Medical 
Data Center Database, a commercial claims database, is less restrictive.17 Although there are 2 
registry databases available in Taiwan that provide significant information, linking them to the 
NHIRD is prohibited due to ethical considerations.16,18 
Due to existing data privacy policies, no individual-level data from the participating 
databases could be shared with researchers from other countries, raising questions about how to 
conduct cross-database studies. A common protocol approach is to have each data partner 
translate their raw data using an identical study protocol into analytic programs.19 Our findings 
indicate we will be able to apply this approach to conduct pharmacoepidemiologic studies, 
including descriptive studies of disease prevalence and incidence, patterns of drugs and health 
recourse utilization, and associated studies, in the current Asian-Pacific database environments. 
Given that date and cause of death are available through direct records or indirect proxy 
measures, studies considering mortality would also be possible. 
A distributed network approach using a common data model can help avoid inconsistency 
in analytical processes that arises from different investigators implementing the study protocol 
differently. This approach executes a systematic program established by a coordinating center on 
a common data format, which enables quality control of the analyses. This also enables analysts 
who are knowledgeable about participating health systems to ensure their data are analyzed and 
interpreted properly.9,20 However, researchers could get entangled in another challenge: the 
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conversion of the database to a common data model structure.9 The common data model could be 
study-specific or could be a global model applied for most routine pharmacoepidemiologic 
studies (eg, the common data model developed by the Observational Medical Outcomes 
Partnership21 or Mini-Sentinel22). Given the diversity of language systems among Asia-Pacific 
countries, the communication of a common format and translations of descriptive information 
stored in databases could be more arduous than in networks where the same language is used. 
According to our survey, information on drugs and diagnoses are recorded by common coding 
systems in the majority of participating databases, which would ease the conversion to a common 
data model. Although NHIRD uses ICD-9 codes for diagnoses, a crosswalk from ICD-9 to ICD-
10 is almost established.23 Nevertheless, many databases use domestic coding system for drugs, 
drug ingredients, strength, and route of administration, which provides a foundation to map these 
codes to an international coding system (eg, ATC codes). We found that the harmonization of 
health expenditure data would be complicated. In addition to challenges in the conversion of 
currency and adjustment of the consumer price index, many categories of health expenditures 
were specific to countries and their health systems. For example, there is no concept of a 
copayment and deductible in Japan, and in Taiwan the dispensing fee is based on the prescription 
and not at the ingredient level,16 both of which differ from some of the other countries. 
Traditional Chinese medicine, including prescribing herbal medications and acupuncture, 
is widely used in all of the countries. We found that utilization data were only available in 
databases in China, Japan, and Taiwan. To our knowledge, no international coding system for 
traditional Chinese medicine currently exists. Consequently, more effort is needed to standard 
relevant terminologies related to traditional Chinese medicine before establishment of a coding 
system, including acupuncture, traumatology, manipulative therapies, and Chinese herbal 
products. 
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In conclusion, we identified multiple databases with the capability to conduct 
collaborative studies using a distributed network approach in the Asia-Pacific region, which 
would enable large-scale surveillance to facilitate prompt identification of emerging safety issues. 
Participating health databases are generally comprehensive in population coverage. Some data 
contents, and many country-specific coding systems and terminologies, have already been 
converted to international coding systems. However, the harmonization of health expenditure data 
presents a major obstacle for future investigations in evaluating issues related to medical cost. 
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Table 1. Database characteristics. 
 
Country 
 
Database name (abbreviation) 
 
Source type 
 
Starting date 
Estimated No. 
of individuals 
Age group 
China Hospital Information System of West China Hospital (HISWCH) 1 hospital EHR August 1, 2008 > 5 million All ages 
Hong Kong Clinical Data Analysis and Reporting System (CDARS) National EHR  January 1, 1995 > 7 million  All ages 
Japan Japan Medical Data Center Database (JMDC) Claims database January 1, 2005 > 2.3 million Mostly < 65 y 
Japanf National Database (NDB) Claims database April 1, 2009 > 128 million All ages 
Korea Korea Health Insurance Review and Assessment Service (HIRA) Claims database December 31, 
2008 
> 50 million All ages 
Singapore National Electronic Health Record (NEHR) National EHR January 1, 2011 > 5 million All ages 
Taiwan National Health Insurance Research Database (NHIRD) Claims database January 1, 1996a > 23 million All ages 
Taiwan Taiwan Stroke Registry (TSR) Registry August 1, 2006 > 100,000  > 18 years 
Taiwan Taiwan Cancer Registry (TCR) Registry June 2003b > 720,000d All ages 
Thailand Buddhachinaraj Hospital Database (BH) 1-hospital EHR January 1, 2008 > 350,000  All ages 
Thailand Hospital Information (HI) 21-hospital EHR January 2003c > 1 million All ages 
Abbreviation: EHR, electronic health record. 
a Medication data is from January 1997. 
b The Taiwan Cancer Registry (TCR) started in 1996 and became nationwide in June 2003. TCR has included patients with cervical cancer patients since 2002, 
extending to patients with breast cancer, oral cavity cancer, lung cancer, hepatocellular carcinoma, and colon/rectal cancer in 2007. In 2008, TCR expanded to 
include patients with prostate cancer, gastric cancer, esophageal cancer, and bladder cancer. TCR has also included patients with nasopharynx cancer, salivary 
gland tumors, uterine sarcoma, ovarian cancer and hematopoietic and lymphoid neoplasms since 2009. 
c Databases from the 21 community hospitals have different starting dates, but every database covers over 10 years (as of December 31, 2013). 
d Approximately 90 000 incident cases per year. 
e All databases are updated continuously. 
f The NDB is not usually available for purchase. Use of the NDB is restricted to individuals with government or academic affiliations, who must apply for 
access. Applications for access typically have a low acceptance rate (about 14% and 30% of all applications in 2011 and 2012, respectively). Information such 
as hospital/clinic/pharmacy identifying information, the number of beds in a hospital, and personal identifiers are typically not shared with users, but these data 
are available in the JMDC. 
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Table 2. Health information in participating databases. 
Source type Claims database Electronic health record Registry 
Data component/database 
N
D
B
 
H
IR
A
 
N
H
IR
D
 
JM
D
C
 
C
D
A
R
S 
N
EH
R
 
B
H
D
 
H
I 
H
IS
-W
C
H
 
TS
R
 
TC
R
 
Patient identifiers   ×       × × × × ×   
Scrambled identifiers  × × ×   × ×     ×   × 
Eligibility of database     × ×     × × × × × 
Demographics                       
Sex × × × × × × × × × × × 
Year of birth × × × × × × × × × × × 
Month of birth   × ×   × × × × × × × 
Date of birth   × ×   × × × × × × × 
Race         × ×   × × ×   
Ethnicity         × ×   × × ×   
Location of patient   × ×a    × × × × × × × 
Other health information                       
Body weight           ×   × × ×   
Body height           ×   × × ×   
Smoking status               ×   ×   
Year of death ×   ×b  × × × × × × ×c × 
Month of death ×    ×b × × × × × × ×c × 
Date of death     ×b   × × × × × ×c × 
Cause of death         × × × × ×  × 
Health records                       
Inpatient × × × × × × × × × × × 
Outpatient × × × × × × × × ×  ×d × 
Emergency room × × × × × × × × ×  ×e × 
Diagnosis  × × × × × × × × × × × 
Drug  × × × × × × × × × × × 
Procedure × × × × × × × × ×  × × 
Type of laboratory test ×   × × × × × × × ×   
Laboratory data value         × × × × × ×   
Health expenditure × ×   ×   × × × ×     
Hospital information                       
Identifiers    ×     × ×   × × ×   
Scrambled identifiers   × × ×   ×     ×   × 
Level of hospital ×f × × ×f   ×   × × × × 
Location of hospital   × ×     ×    × × × × 
Physician information            
Identifiers            ×   × ×     
Scrambled identifiers      ×     ×           
Specialty ×g × × ×g    ×   × × ×   
Starting date of specialty      ×     ×     ×     
Year of birth     ×         ×       
Month of birth     ×         ×       
Date of birth     ×                 
Sex     ×     ×   ×       
Place of service     ×     ×   ×       
Abbreviations: BHD, Buddhachinaraj Hospital Database (Thailand); CDARS, Clinical Data Analysis and Reporting 
System (Hong Kong); HI, Hospital Information (Ubon Ratchathani, Thailand); HIRA, Health Insurance Review 
and Assessment (South Korea); HIS-WCH, Hospital Information System of West China Hospital; JMDC, Japan 
16 
Medical Data Center; NDB, National Database (Japan); NEHR, National Electronic Health Record (Singapore); 
NHIRD, National Health Insurance Research Database (Taiwan); TCR, Taiwan Cancer Registry; TSR, Taiwan 
Stroke Registry. 
a Determined using the zip code in the National Health Insurance Research Database. 
b Determined using the date of disenrollment date from Taiwanese national insurance. 
c Only for death within 6 months after stroke events. 
d Summary of stroke-related medication use before the index stroke event, and outpatient visits at 1, 3, and 6 months 
after the index stroke event. 
e Summary of emergency department visits for the index stroke event. 
f Determined using the number of beds in the hospital. 
g Determined using the department name or specialty of the physician’s clinic. 
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Table 3. Detailed information on medications, diagnoses, procedures, and health expenditures in participating databases. 
Source type Claims database Electronic health record Registry 
Data component/ 
database  
N
D
B
 
H
IR
A
 
N
H
IR
D
 
JM
D
C
 
C
D
A
R
S 
N
EH
R
 
B
H
D
 
H
I 
H
IS
-
W
C
H
 
TS
R
 
TC
R
 
Drug information            
Domestic coding system × × × × × × × × ×   
International coding system ATCa ATCa ATCa ATCa BNF   ATC    
Prescription place of service  × ×  × × × × × ×  
Prescription date × × × × × × × × × ×b ×c 
Dispensing pharmacist  × ×   ×  × ×   
Dispensing date × × × × × × × × × ×b  
Drug supply day  × × × × × × × × × ×b  
Quantity  × × × × × × × × × ×b  
Route or drug administration  × × × × × × × × × ×b  
Dose strength  × × × × × × × × × ×b  
Usage frequency  × × × × × × × × × ×b  
Specific indication       × × × × ×b  
Reason for discontinuation      ×  ×  ×b  
Diagnosis information            
Domestic coding system     ×    ×   
International coding system ICD 10 ICD 10 ICD 9 ICD 10 ICD 9/ 
ICD 10 
ICD 10 ICD 10 ICD 10 ICD 10 ICD 9 ICD 9 
Diagnosis start date × × × × ×  × × × × × 
Diagnosis end date ×   ×   × ×  ×  
Diagnosis stop reason ×   ×    ×  ×  
Procedure information            
Domestic coding system  × × × × ×  ×  ×  × 
International coding system   ICD 9  ICD 9 ICD 9  ICD 9    
Procedure place of service  × ×  ×  × × × × × 
Procedure date × × × × ×  × × ×  × 
Specific indication    ×     × ×   
Health expenditure information             
Total paid per visit ×d × × ×d  × × × ×   
Total drug payments  × ×e   ×      
Total procedure payments      ×      
Copayment  N/Af × × N/Af  ×  × ×   
Coinsurance ×g ×  ×g  ×  ×    
18 
Paid by payer  ×h × N/Af ×h  ×      
Paid by coordination benefits  N/Af × N/Af N/Af  ×      
Abbreviations: Anatomical Therapeutic Chemical Classification System; BHD, Buddhachinaraj Hospital Database (Thailand); BNF, British National Formulary; 
CDARS, Clinical Data Analysis and Reporting System (Hong Kong); HI, Hospital Information (Ubon Ratchathani, Thailand); HIRA, Health Insurance Review 
and Assessment (South Korea); HIS-WCH, Hospital Information System of West China Hospital; ICD, International Classification of Diseases; JMDC, Japan 
Medical Data Center; NDB, National Database (Japan); NEHR, National Electronic Health Record (Singapore); NHIRD, National Health Insurance Research 
Database (Taiwan); TCR, Taiwan Cancer Registry; TSR, Taiwan Stroke Registry. 
a Converted by the database partner. 
b Only for the prescription date and route, and reasons for discontinuing thrombolytic therapy with alteplase. 
c Only for the first regimen of chemotherapy. 
d Total payments for health care services per month. 
e The dispensing fee is based on prescription but not at the ingredient level. 
f No relevant concept in the country. 
g The information for patient type with fixed percentage coinsurance. 
h The information for patient type with fixed percentage paid by payer. 
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Table 4. Information on Chinese herbal products. 
Data component/database  NDB JMDC NHIRD HIS-WCH 
Diagnosis   × × 
Procedure ×a ×a × × 
Chinese herbal products     
Domestic coding system × × × × 
International coding system     
Prescription place of service   × × 
Prescription date × × × × 
Dispensing pharmacist × × × × 
Dispensing date × × × × 
Drug supply day  × × × × 
Quantity  × × × × 
Route or drug administration × × × × 
Dose strength  × × × × 
Usage frequency  × × × × 
Specific indication     × 
Reason for discontinuation    × 
Abbreviations: HIS-WCH, Hospital Information System of West China Hospital; JMDC, Japan 
Medical Data Center; NDB, National Database (Japan); NHIRD, National Health Insurance 
Research Database (Taiwan). 
a Acupuncture is covered by health insurance only for specific diseases in special cases. Only a 
small proportion of acupuncture records are available in the databases. 
